Japan’s PMDA Introduces Data Mining To Detect Adverse Events Earlier
This article was originally published in PharmAsia News
Starting in fiscal year 2009, the Pharmaceuticals and Medical Device Agency of Japan plans to experiment with data mining techniques to detect earlier safety issues in drugs and medical devices. As a key element of a safety assurance system introduced in 2004, data mining will be used to understand drug risks at early stages and to prevent expansion of adverse events. PMDA said that the data mining system has been completed, and that a new adverse event database will also launch in 2009. Data mining has been used by the U.S. FDA and World Health Organization. (Click here for more - Japanese language
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.